CClinicalTrials.gg
CompletedNCT00660049Updated Dec 13, 2017Results posted

Feasibility Study of a Novel Device for Chronic Wounds

An interventional study of SNaP Advanced Wound Care System and SNaP in Ulcer and Wounds and Injuries, sponsored by Stanford University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-13.

Sponsored by Stanford University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the feasibility and usability of a new portable and compact wound dressing device for the treatment of small chronic skin wounds.

Read the detailed description

This is an open label study

02

Conditions studied

  • Ulcer
  • Wounds and Injuries

Browse trials for

03

In context

Wounds and Injuries

5,056 studies on the registry are indexed under Wounds and Injuries; 861 are open to participants now.

This study's enrollment of 12 is below the median of 52 across 3,239 interventional studies indexed under Wounds and Injuries.

Browse Wounds and Injuries studies →

Lead sponsor

Stanford University is the lead sponsor of 2,117 studies on the registry; 425 are open to participants now.

Of its 259 completed or terminated interventional studies of FDA-regulated products, 197 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:- Venous stasis ulcer or other chronic wound on the lower extremity that is >1.5cm and \<10cm at widest point

  • The wound must have at least 2 cm of intact epithelium surrounding it.
  • A wound such as a pressure ulcer or chronic ulcer on a location other than the lower extremity may also be included in the study if it meets the size requirements and a reliable seal can be achieved.
  • Ulcer must not have healed for >14 days under standard treatment.
  • Chronic wound with prior graft placement will be allowed in the study.
  • Patient is >18 years old.
  • Willing and able to sign informed consent.

Exclusion Criteria:- Active wound infection.

  • 3+ or greater pitting edema of lower extremity
  • History of malignancy at wound site. However, wounds that are closing by secondary intent after surgical clearance of prior tumor will be allowed in the study.
  • Thick eschar at wound base after debridement.
  • Wound location is not amenable to forming an airtight seal and placement of device.
  • Ulcers due to inflammatory conditions such as pyoderma gangrenosum, rheumatoid arthritis, vasculitis, cryoglobulinemia, necrobiosis lipoidica diabeticorum, lupus or pancreatic panniculitis, cryofibrinogenemia, calcinosis cutis, scleroderma, Raynaud's syndrome.
  • Current smoker (must have quit for >3 weeks)
  • Wound with exposed bone, blood vessels, tendon
  • Significant immunosuppression (as determined by the investigator and sponsor) such as high dose prednisone
  • Fasting blood sugar >200 by study personnel administered bedside fingerstick blood glucose
  • Ankle brachial index less than lower limit of normal (\<0.60) as performed and determined by licensed physician (necessary only for patients with lower extremity wounds).
  • Pregnancy
  • Incapable of giving informed consent
  • Inability to comply with study procedures including lack of telephone access for week 8 telephone survey
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    SNaP application

    This is an "open label" pilot study of SNaP Advanced Wound Care System

    Device: SNaP Advanced Wound Care System · Other: SNaP

Interventions

  • DeviceSNaP Advanced Wound Care System

    Application of negative pressure device daily per instructions

    Also known as: SNaP device (SmartNegative Pressure device)

  • OtherSNaP

    Daily use

    Also known as: SNaP device

  • OtherSNaP

    Daily application per protocol

06

What researchers measure

Primary outcomes

  1. Ease of Use for Patients

    Participants were given instructions to use the SNaP device home. Participants completed a questionnaire reporting whether the device was easy to use, worthwhile to use, and whether they would use the device again. Numbers responding positively to each question are presented.

    Time frame: Baseline up to 31 days

07

Results

Posted Jan 20, 2017
Limitations and caveats
Open label design without comparator arm

Participant flow

Participant flow — Overall Study
MilestoneSNaP Application
Started12
Completed6
Not completed6

Outcome measures

PrimaryEase of Use for Patients

Participants were given instructions to use the SNaP device home. Participants completed a questionnaire reporting whether the device was easy to use, worthwhile to use, and whether they would use the device again. Numbers responding positively to each question are presented.

Time frame:
Baseline up to 31 days
Reported as:
Number · participants
Ease of Use for Patients
participantsOpen Label Single Arm Study
Easy to use8
Worthwhile to use10
I would use this device again9

Adverse events

Collected over 1 month. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eligible Participants—0/12 (0%)4/12 (33.3%)
Most frequent other events
Most frequent other events
EventEligible Participants
ipsilateral knee painMusculoskeletal and connective tissue disorders3/11
wound painSkin and subcutaneous tissue disorders3/12

Baseline characteristics

12

Age, Categorical
Age, Categorical(Participants)Open Label Single Arm Study
<=18 years0
Between 18 and 65 years9
>=65 years3
Age, Continuous
Age, Continuous(years)Open Label Single Arm Study
Median55 (18 to 86)
Sex: Female, Male
Sex: Female, Male(Participants)Open Label Single Arm Study
Female7
Male5
Region of Enrollment
Region of Enrollment(participants)Open Label Single Arm Study
United States12
08

Study locations

1 site
  • Stanford University School of Medicine
    Stanford, California 94305, United States
09

References and documents

Publications

  • Fong KD, Hu D, Eichstadt SL, Gorell E, Munoz CA, Lorenz HP, Chang AL. Initial clinical experience using a novel ultraportable negative pressure wound therapy device. Wounds. 2010 Sep;22(9):230-6. PubMed 25901554 ↗

Individual participant data

Plan to share: No — No sharing

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00660049
Lead sponsor
Stanford University
Collaborators
3M
Responsible party
Anne Chang (Professor, Stanford University) — Principal investigator
First posted
Apr 17, 2008
Start date
Mar 2008
Primary completion
Jul 2010
Completion
Aug 2010
Results posted
Jan 20, 2017
Last update
Dec 13, 2017

Study contacts

Dr. Anne Lynn S. Chang
principal investigator · Stanford University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion